Robert W. Baird Reaffirms “Hold” Rating for DaVita HealthCare Partners Inc. (DVA)
Robert W. Baird reaffirmed their hold rating on shares of DaVita HealthCare Partners Inc. (NYSE:DVA) in a research report released on Friday. Robert W. Baird currently has a $63.00 price target on the stock.
DVA has been the subject of a number of other reports. Royal Bank Of Canada reaffirmed a hold rating and set a $64.00 price objective on shares of DaVita HealthCare Partners in a research report on Wednesday, September 6th. J P Morgan Chase & Co cut DaVita HealthCare Partners from a neutral rating to an underweight rating in a report on Monday, October 9th. SunTrust Banks, Inc. set a $57.00 price target on DaVita HealthCare Partners and gave the company a hold rating in a report on Sunday, October 15th. BidaskClub cut DaVita HealthCare Partners from a sell rating to a strong sell rating in a report on Saturday, August 5th. Finally, TheStreet cut DaVita HealthCare Partners from a b rating to a c+ rating in a report on Wednesday, August 2nd. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. DaVita HealthCare Partners currently has a consensus rating of Hold and a consensus price target of C$63.00.
Shares of DaVita HealthCare Partners (DVA) opened at C$55.00 on Friday. DaVita HealthCare Partners has a 1 year low of C$52.51 and a 1 year high of C$70.16. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40. The firm has a market capitalization of $10,407.74, a P/E ratio of 15.71, a price-to-earnings-growth ratio of 11.05 and a beta of 0.98.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings data on Tuesday, November 7th. The company reported C$0.81 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.94 by C($0.13). DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The company had revenue of C$3.92 billion for the quarter, compared to analyst estimates of C$3.91 billion. During the same period in the previous year, the business posted $0.95 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. equities analysts predict that DaVita HealthCare Partners will post 3.43 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/robert-w-baird-reaffirms-hold-rating-for-davita-healthcare-partners-inc-dva/1699398.html.
DaVita HealthCare Partners declared that its Board of Directors has initiated a stock repurchase program on Tuesday, October 10th that permits the company to buyback $1.50 billion in shares. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.
A number of hedge funds have recently modified their holdings of the stock. Pzena Investment Management LLC raised its holdings in DaVita HealthCare Partners by 2.1% during the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after purchasing an additional 71 shares during the last quarter. Eqis Capital Management Inc. raised its holdings in DaVita HealthCare Partners by 2.2% during the second quarter. Eqis Capital Management Inc. now owns 4,600 shares of the company’s stock worth $298,000 after purchasing an additional 100 shares during the last quarter. Thrivent Financial For Lutherans raised its holdings in DaVita HealthCare Partners by 4.4% during the first quarter. Thrivent Financial For Lutherans now owns 5,730 shares of the company’s stock worth $389,000 after purchasing an additional 240 shares during the last quarter. Founders Capital Management LLC raised its holdings in DaVita HealthCare Partners by 0.6% during the second quarter. Founders Capital Management LLC now owns 93,824 shares of the company’s stock worth $6,076,000 after purchasing an additional 520 shares during the last quarter. Finally, Speece Thorson Capital Group Inc. raised its holdings in DaVita HealthCare Partners by 0.5% during the second quarter. Speece Thorson Capital Group Inc. now owns 280,515 shares of the company’s stock worth $18,166,000 after purchasing an additional 1,360 shares during the last quarter. 84.73% of the stock is owned by hedge funds and other institutional investors.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.